<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33670164</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>The Role of the Inflammasome in Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">953</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules26040953</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are chronic, progressive disorders that occur in the central nervous system (CNS). They are characterized by the loss of neuronal structure and function and are associated with inflammation. Inflammation of the CNS is called neuroinflammation, which has been implicated in most neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Much evidence indicates that these different conditions share a common inflammatory mechanism: the activation of the inflammasome complex in peripheral monocytes and in microglia, with the consequent production of high quantities of the pro-inflammatory cytokines IL-1&#x3b2; and IL-18. Inflammasomes are a group of multimeric signaling complexes that include a sensor Nod-like receptor (NLR) molecule, the adaptor protein ASC, and caspase-1. The NLRP3 inflammasome is currently the best-characterized inflammasome. Multiple signals, which are potentially provided in combination and include endogenous danger signals and pathogens, trigger the formation of an active inflammasome, which, in turn, will stimulate the cleavage and the release of bioactive cytokines including IL-1&#x3b2; and IL-18. In this review, we will summarize results implicating the inflammasome as a pivotal player in the pathogenesis of neurodegenerative diseases and discuss how compounds that hamper the activation of the NLRP3 inflammasome could offer novel therapeutic avenues for these diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piancone</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, 20148 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Rosa</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, 20148 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marventano</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, 20148 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saresella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, 20148 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clerici</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5920-6191</Identifier><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, 20148 Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milano, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020382">Interleukin-18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020382" MajorTopicYN="N">Interleukin-18</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">NLRP3 inflammasome</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s diseases</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">inflammasome</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33670164</ArticleId><ArticleId IdType="pmc">PMC7916884</ArticleId><ArticleId IdType="doi">10.3390/molecules26040953</ArticleId><ArticleId IdType="pii">molecules26040953</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schain M., Kreisl W.C. Neuroinflammation in neurodegenerative disorders-a review. Curr. Neurol. Neurosci. Rep. 2017;17:25. doi: 10.1007/s11910-017-0733-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0733-2</ArticleId><ArticleId IdType="pubmed">28283959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W.W., Zhang X., Huang W.J. Role of neuroinflammation in neurodegenerative diseases. Mol. Med. Rep. 2016;13:3391&#x2013;3396. doi: 10.3892/mmr.2016.4948.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.4948</ArticleId><ArticleId IdType="pmc">PMC4805095</ArticleId><ArticleId IdType="pubmed">26935478</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Cheng X., Zhong S., Liu C., Liu F., Zhao C. Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis. Front. Neurosci. 2020;14:575. doi: 10.3389/fnins.2020.00575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00575</ArticleId><ArticleId IdType="pmc">PMC7308438</ArticleId><ArticleId IdType="pubmed">32612503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccocioppo F., Bologna G., Ercolino E., Pierdomenico L., Simeone P., Lanuti P., Pieragostino D., Del Boccio P., Marchisio M., Miscia S. Neurodegenerative diseases as proteinopathies-driven immune disorders. Neural. Regen. Res. 2020;15:850&#x2013;856. doi: 10.4103/1673-5374.268971.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.268971</ArticleId><ArticleId IdType="pmc">PMC6990794</ArticleId><ArticleId IdType="pubmed">31719246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer T.A. Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? Eur. Neuropsychopharmacol. 2015;25:713&#x2013;724. doi: 10.1016/j.euroneuro.2013.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2013.03.007</ArticleId><ArticleId IdType="pubmed">23642796</ArticleId></ArticleIdList></Reference><Reference><Citation>Sami N., Rahman S., Kumar V., Zaidi S., Islam A., Ali S., Ahmad F., Hassan M.I. Protein aggregation, misfolding and consequential human neurodegenerative diseases. Int. J. Neurosci. 2017;127:1047&#x2013;1057. doi: 10.1080/00207454.2017.1286339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2017.1286339</ArticleId><ArticleId IdType="pubmed">28110595</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C., Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 2018;21:1332&#x2013;1340. doi: 10.1038/s41593-018-0235-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId><ArticleId IdType="pmc">PMC6432913</ArticleId><ArticleId IdType="pubmed">30250260</ArticleId></ArticleIdList></Reference><Reference><Citation>Strowig T., Henao-Mejia J., Elinav E., Flavell R. Inflammasomes in health and disease. Nature. 2012;481:278&#x2013;286. doi: 10.1038/nature10759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10759</ArticleId><ArticleId IdType="pubmed">22258606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M., Dixit V.M. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013&#x2013;1022. doi: 10.1016/j.cell.2014.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.04.007</ArticleId><ArticleId IdType="pubmed">24855941</ArticleId></ArticleIdList></Reference><Reference><Citation>Broz P., Dixit V.M. Inflammasomes: Mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 2016;16:407&#x2013;420. doi: 10.1038/nri.2016.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.58</ArticleId><ArticleId IdType="pubmed">27291964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M., Dixit V.M. Inflammasomes and their roles in health and disease. Ann. Rev. Cell. Dev. Biol. 2012;28:137&#x2013;161. doi: 10.1146/annurev-cellbio-101011-155745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-101011-155745</ArticleId><ArticleId IdType="pubmed">22974247</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Liu Z., Xiao T.S. Post-translational regulation of inflammasomes. Cell. Mol. Immunol. 2017;14:65&#x2013;79. doi: 10.1038/cmi.2016.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2016.29</ArticleId><ArticleId IdType="pmc">PMC5214939</ArticleId><ArticleId IdType="pubmed">27345727</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J.Q., Zhang C.C., Sun X.L., Cheng X.X., Wang J.B., Zhang Y.D., Xu J., Zou H.Q. Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-kappaB and NLRP3 inflammasome activation. CNS. Neurosci. Ther. 2013;19:262&#x2013;268. doi: 10.1111/cns.12066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12066</ArticleId><ArticleId IdType="pmc">PMC6493386</ArticleId><ArticleId IdType="pubmed">23406388</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan S.M. Pragmatic target discovery from novel gene to functionally defined drug target: The interleukin-1 story. Methods Mol. Med. 2005;104:333&#x2013;346. doi: 10.1385/1-59259-836-6:333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/1-59259-836-6:333</ArticleId><ArticleId IdType="pubmed">15454676</ArticleId></ArticleIdList></Reference><Reference><Citation>Alboni S., Cervia D., Sugama S., Conti B. Interleukin 18 in the CNS. J. Neuroinflamm. 2010;7:9. doi: 10.1186/1742-2094-7-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-9</ArticleId><ArticleId IdType="pmc">PMC2830964</ArticleId><ArticleId IdType="pubmed">20113500</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad F., Assrawi E., Jumeau C., Georgin-Lavialle S., Cobret L., Duquesnoy P., Piterboth W., Thomas L., Stankovic-Stojanovic K., Louvrier C., et al. Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation. PLoS ONE. 2017;12:e0175336. doi: 10.1371/journal.pone.0175336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0175336</ArticleId><ArticleId IdType="pmc">PMC5389804</ArticleId><ArticleId IdType="pubmed">28403163</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T.C., et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>La Rosa F., Saresella M., Marventano I., Piancone F., Ripamonti E., Al-Daghri N., Bazzini C., Zoia C.P., Conti E., Ferrarese C., et al. Stavudine Reduces NLRP3 Inflammasome Activation and Modulates Amyloid-&#x3b2; Autophagy. J. Alzheimers Dis. 2019;72:401&#x2013;412. doi: 10.3233/JAD-181259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-181259</ArticleId><ArticleId IdType="pubmed">31594217</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M., La Rosa F., Piancone F., Zoppis M., Marventano I., Calabrese E., Rainone V., Nemni R., Mancuso R., Clerici M. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2016;11:1&#x2013;14. doi: 10.1186/s13024-016-0088-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0088-1</ArticleId><ArticleId IdType="pmc">PMC4778358</ArticleId><ArticleId IdType="pubmed">26939933</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-&#x3b2;. Nat. Immunol. 2008;9:857&#x2013;865. doi: 10.1038/ni.1636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1636</ArticleId><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T. Inflammasome activation and innate immunity in Alzheimer&#x2019;s disease. Brain Pathol. 2017;27:220&#x2013;222. doi: 10.1111/bpa.12483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12483</ArticleId><ArticleId IdType="pubmed">28019679</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey C., Rubio Araiz A., Bryson K.J., Finucane O., Larkin C., Mills E.L., Robertson A.A.B., Cooper M.A., O&#x2019;Neill L.A.J., Lynch M.A. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-&#x3b2; and cognitive function in APP/PS1 mice. Brain Behav. Immun. 2017;61:306&#x2013;316. doi: 10.1016/j.bbi.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.12.014</ArticleId><ArticleId IdType="pubmed">28003153</ArticleId></ArticleIdList></Reference><Reference><Citation>Parajuli B., Sonobe Y., Horiuchi H., Takeuchi H., Mizuno T., Suzumura A. Oligomeric amyloid &#x3b2; induces IL-1&#x3b2; processing via production of ROS: Implication in Alzheimer&#x2019;s disease. Cell Death Dis. 2013;4:e975. doi: 10.1038/cddis.2013.503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.503</ArticleId><ArticleId IdType="pmc">PMC3877570</ArticleId><ArticleId IdType="pubmed">24357806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontillo A., Catamo E., Arosio B., Mari D., Crovella S. NALP1/NLRP1 genetic variants are associated with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012;26:277&#x2013;281. doi: 10.1097/WAD.0b013e318231a8ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318231a8ac</ArticleId><ArticleId IdType="pubmed">21946017</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M.S., Tan L., Jiang T., Zhu X.C., Wang H.F., Jia C.D., Yu J.T. Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer&#x2019;s disease. Cell Death Dis. 2014;5:e1382. doi: 10.1038/cddis.2014.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.348</ArticleId><ArticleId IdType="pmc">PMC4454321</ArticleId><ArticleId IdType="pubmed">25144717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushal V., Dye R., Pakavathkumar P., Foveau B., Flores J., Hyman B., Ghetti B., Koller B.H., LeBlanc A.C. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 2015;22:1676&#x2013;1686. doi: 10.1038/cdd.2015.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.16</ArticleId><ArticleId IdType="pmc">PMC4563782</ArticleId><ArticleId IdType="pubmed">25744023</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai-Zadeh K., Gate D., Gowing G., Town T. How to get from here to there: Macrophage recruitment in Alzheimer&#x2019;s disease. Curr. Alzheimer Res. 2011;8:156&#x2013;163. doi: 10.2174/156720511795256017.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511795256017</ArticleId><ArticleId IdType="pmc">PMC3086574</ArticleId><ArticleId IdType="pubmed">21345166</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C.M., Pereira J.R., de Andrade L.P., Garuffi M., Talib L.L., Forlenza O.V., Cancela J.M., Cominetti M.R., Stella F. Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr. Alzheimer Res. 2014;11:799&#x2013;805. doi: 10.2174/156720501108140910122849.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720501108140910122849</ArticleId><ArticleId IdType="pubmed">25212919</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionisio-Santos D.A., Olschowka J.A., O&#x2019;Banion M.K. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer&#x2019;s disease. J. Neuroinflamm. 2019;16:74. doi: 10.1186/s12974-019-1453-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1453-0</ArticleId><ArticleId IdType="pmc">PMC6449993</ArticleId><ArticleId IdType="pubmed">30953557</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T., Tan J., Mullan M. CD40 signaling and Alzheimer&#x2019;s disease pathogenesis. Neurochem. Int. 2001;39:371&#x2013;380. doi: 10.1016/S0197-0186(01)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(01)00044-4</ArticleId><ArticleId IdType="pubmed">11578772</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T., Nikolic V., Tan J. The microglial &#x201c;activation&#x201d; continuum: From innate to adaptive responses. J. Neuroinflamm. 2005;2:24. doi: 10.1186/1742-2094-2-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-24</ArticleId><ArticleId IdType="pmc">PMC1298325</ArticleId><ArticleId IdType="pubmed">16259628</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T., Laouar Y., Pittenger C., Mori T., Szekely C.A., Tan J., Duman R.S., Flavell R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008;14:681&#x2013;687. doi: 10.1038/nm1781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1781</ArticleId><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C.A., McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. USA. 2009;106:1261&#x2013;1266. doi: 10.1073/pnas.0805453106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805453106</ArticleId><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M.S., Yu J.T., Jiang T., Zhu X.C., Tan L. The NLRP3 inflammasome in Alzheimer&#x2019;s disease. Mol. Neurobiol. 2013;48:875&#x2013;882. doi: 10.1007/s12035-013-8475-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8475-x</ArticleId><ArticleId IdType="pubmed">23686772</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend K.P., Town T., Mori T., Lue L.F., Shytle D., Sanberg P.R., Morgan D., Fernandez F., Flavell R.A., Tan J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur. J. Immunol. 2005;35:901&#x2013;910. doi: 10.1002/eji.200425585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200425585</ArticleId><ArticleId IdType="pubmed">15688347</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y., Li L., Sun X.H. Monocytes and Alzheimer&#x2019;s disease. Neurosci. Bull. 2011;2:115&#x2013;122. doi: 10.1007/s12264-011-1205-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-011-1205-3</ArticleId><ArticleId IdType="pmc">PMC5560348</ArticleId><ArticleId IdType="pubmed">21441973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., Patel A., Lossinsky A.S., Graves M.C., Gustavson A., Sayre J., et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer&#x2019;s disease patients. J. Alzheimers Dis. 2005;3:221&#x2013;232. doi: 10.3233/JAD-2005-7304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2005-7304</ArticleId><ArticleId IdType="pubmed">16006665</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A.R., Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer&#x2019;s disease. Mol. Psychiatry. 2006;11:327&#x2013;335. doi: 10.1038/sj.mp.4001809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001809</ArticleId><ArticleId IdType="pubmed">16491130</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M., Marventano I., Calabrese E., Piancone F., Rainone V., Gatti A., Alberoni M., Nemni R., Clerici M. A complex proinflammatory role for peripheral monocytes in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2014;38:403&#x2013;413. doi: 10.3233/JAD-131160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131160</ArticleId><ArticleId IdType="pubmed">23979026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo A., Cattane N., Galluzzi S., Provasi S., Lopizzo N., Festari C., Ferrari C., Guerra U.P., Paghera B., Muscio C., et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging. 2017;49:60&#x2013;68. doi: 10.1016/j.neurobiolaging.2016.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.08.019</ArticleId><ArticleId IdType="pubmed">27776263</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M., Basilico N., Marventano I., Perego F., La Rosa F., Piancone F., Taramelli D., Banks H., Clerici M. Leishmania infantum infection reduces the amyloid &#x3b2;42-stimulated NLRP3 inflammasome activation. Brain Behav. Immun. 2020;88:597&#x2013;605. doi: 10.1016/j.bbi.2020.04.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.058</ArticleId><ArticleId IdType="pubmed">32335194</ArticleId></ArticleIdList></Reference><Reference><Citation>Trumble B.C., Stieglitz J., Blackwell A.D., Allayee H., Beheim B., Finch C.E., Gurven M., Kaplan H. Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden. FASEB J. 2017;31:1508&#x2013;1515. doi: 10.1096/fj.201601084R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201601084R</ArticleId><ArticleId IdType="pmc">PMC5349792</ArticleId><ArticleId IdType="pubmed">28031319</ArticleId></ArticleIdList></Reference><Reference><Citation>Baecher-Allan C., Kaskow B.J., Weiner H.W. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018;97:742&#x2013;768. doi: 10.1016/j.neuron.2018.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.021</ArticleId><ArticleId IdType="pubmed">29470968</ArticleId></ArticleIdList></Reference><Reference><Citation>Gris D., Ye Z., Iocca H.A., Wen H., Craven R.R., Gris P., Huang M., Schneider M., Miller S.D., Ting J.P. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010;185:974&#x2013;981. doi: 10.4049/jimmunol.0904145.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0904145</ArticleId><ArticleId IdType="pmc">PMC3593010</ArticleId><ArticleId IdType="pubmed">20574004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R.M. Animal models of multiple sclerosis: The good, the bad and the bottom line. Nat. Neurosci. 2012;15:1074&#x2013;1077. doi: 10.1038/nn.3168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3168</ArticleId><ArticleId IdType="pmc">PMC7097342</ArticleId><ArticleId IdType="pubmed">22837037</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelen E., Damoiseaux J., Muris A.H., Knippenberg S., Smolders J., Hupperts R., Thewissen M. Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. Mol. Immunol. 2015;63:521&#x2013;529. doi: 10.1016/j.molimm.2014.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2014.10.008</ArticleId><ArticleId IdType="pubmed">25458313</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M., Shinohara M.L. NLRP3 Inflammasome and MS/EAE. Autoimmune Dis. 2013;2013:859145. doi: 10.1155/2013/859145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/859145</ArticleId><ArticleId IdType="pmc">PMC3556409</ArticleId><ArticleId IdType="pubmed">23365725</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamik M.K., Power C. Inflammasomes in neurological diseases: Emerging pathogenic and therapeutic concepts. Brain. 2017;140:2273&#x2013;2285. doi: 10.1093/brain/awx133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx133</ArticleId><ArticleId IdType="pubmed">29050380</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan R., Filippi M., Bergami A., Rocca M.A., Martinelli V., Poliani P.L., Grimaldi L.M., Desina G., Comi G., Martino G. Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. J. Neurol. Neurosurg. Psychiatry. 1999;67:785&#x2013;788. doi: 10.1136/jnnp.67.6.785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.67.6.785</ArticleId><ArticleId IdType="pmc">PMC1736665</ArticleId><ArticleId IdType="pubmed">10567499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming X., Li W., Maeda Y., Blumberg B., Raval S., Cook S.D., Dowling P.C. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J. Neurol. Sci. 2002;197:9&#x2013;18. doi: 10.1016/S0022-510X(02)00030-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(02)00030-8</ArticleId><ArticleId IdType="pubmed">11997061</ArticleId></ArticleIdList></Reference><Reference><Citation>Keane R.W., Dietrich W.D., de Rivero Vaccari J.P. Inflammasome Proteins As Biomarkers of Multiple Sclerosis. Front. Neurol. 2018;9:135. doi: 10.3389/fneur.2018.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00135</ArticleId><ArticleId IdType="pmc">PMC5868457</ArticleId><ArticleId IdType="pubmed">29615953</ArticleId></ArticleIdList></Reference><Reference><Citation>Losy J., Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurol. Scand. 2001;104:171&#x2013;173. doi: 10.1034/j.1600-0404.2001.00356.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2001.00356.x</ArticleId><ArticleId IdType="pubmed">11551238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti F., Di Marco R., Mangano K., Patti F., Reggio E., Nicoletti A., Bendtzen K., Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology. 2001;57:342&#x2013;344. doi: 10.1212/WNL.57.2.342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.2.342</ArticleId><ArticleId IdType="pubmed">11468327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.C., Chen S.D., Miao L., Liu Z.G., Li W., Zhao Z.X., Sun X.J., Jiang G.X., Cheng Q. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J. Neuroimmunol. 2012;243:56&#x2013;60. doi: 10.1016/j.jneuroim.2011.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2011.12.008</ArticleId><ArticleId IdType="pubmed">22230485</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jong B.A., Huizinga T.W., Bollen E.L., Uitdehaag B.M., Bosma G.P., van Buchem M.A., Remarque E.J., Burgmans A.C., Kalkers N.F., Polman C.H., et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J. Neuroimmunol. 2002;126:172&#x2013;179. doi: 10.1016/S0165-5728(02)00056-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(02)00056-5</ArticleId><ArticleId IdType="pubmed">12020968</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger D., Molnarfi N., Weber M.S., Brandt K.J., Benkhoucha M., Gruaz L., Chofflon M., Zamvil S.S., Lalive P.H. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1&#x3b2; in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2009;106:4355&#x2013;4359. doi: 10.1073/pnas.0812183106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812183106</ArticleId><ArticleId IdType="pmc">PMC2649955</ArticleId><ArticleId IdType="pubmed">19255448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti F., Patti F., DiMarco R., Zaccone P., Nicoletti A., Meroni P., Reggio A. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-&#x3b2; treatment. Cytokine. 1996;8:395&#x2013;400. doi: 10.1006/cyto.1996.0054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.1996.0054</ArticleId><ArticleId IdType="pubmed">8726668</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin B.N., Wang C., Zhang C.J., Kang Z., Gulen M.F., Zepp J.A., Zhao J., Bian G., Do J.S., Min B., et al. T cell-intrinsic ASC critically promotes T(H)17-mediated experimental autoimmune encephalomyelitis. Nat. Immunol. 2016;17:583&#x2013;592. doi: 10.1038/ni.3389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3389</ArticleId><ArticleId IdType="pmc">PMC5385929</ArticleId><ArticleId IdType="pubmed">26998763</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierini R., Perret M., Djebali S., Juruj C., Michallet M.C., F&#xf6;rster I., Marvel J., Walzer T., Henry T. ASC controls IFN-&#x3b3; levels in an IL-18-dependent manner in caspase-1-deficient mice infected with Francisella novicida. J. Immunol. 2013;191:3847&#x2013;3857. doi: 10.4049/jimmunol.1203326.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203326</ArticleId><ArticleId IdType="pubmed">23975862</ArticleId></ArticleIdList></Reference><Reference><Citation>Amorini A.M., Petzold A., Tavazzi B., Eikelenboom J., Keir G., Belli A., Giovannoni G., Di Pietro V., Polman C., D&#x2019;Urso S., et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin. Biochem. 2009;42:1001&#x2013;1006. doi: 10.1016/j.clinbiochem.2009.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2009.03.020</ArticleId><ArticleId IdType="pubmed">19341721</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Shen Y., Xiao K., Tang Y., Cen L., Wei J. Serum uric acid levels in patients with multiple sclerosis: A meta-analysis. Neurol. Res. 2012;34:163&#x2013;171. doi: 10.1179/1743132811Y.0000000074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132811Y.0000000074</ArticleId><ArticleId IdType="pubmed">22333889</ArticleId></ArticleIdList></Reference><Reference><Citation>Piancone F., Saresella M., Marventano I., La Rosa F., Santangelo M.A., Caputo D., Mendozzi L., Rovaris M., Clerici M. Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. Front. Immunol. 2018;9:983. doi: 10.3389/fimmu.2018.00983.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00983</ArticleId><ArticleId IdType="pmc">PMC5945820</ArticleId><ArticleId IdType="pubmed">29780394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. doi: 10.1186/1471-2377-6-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>Matute C. Interaction between glutamate signalling and immune attack in damaging oligodendrocytes. Neuron. Glia. Biol. 2007;3:281&#x2013;285. doi: 10.1017/S1740925X08000033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1740925X08000033</ArticleId><ArticleId IdType="pubmed">18634560</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyanguren-Desez O., Rodriguez-Antiguedad A., Villoslada P., Domercq M., Alberdi E., Matute C. Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium. 2011;50:468&#x2013;472. doi: 10.1016/j.ceca.2011.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2011.08.002</ArticleId><ArticleId IdType="pubmed">21906809</ArticleId></ArticleIdList></Reference><Reference><Citation>Caragnano M., Tortorella P., Bergami A., Ruggieri M., Livrea P., Specchio L.M., Martino G., Trojano M., Furlan R., Avolio C. Monocytes P2X7 purinergic receptor is modulated byglatiramer acetate in multiple sclerosis. J. Neuroimmunol. 2012;245:93&#x2013;97. doi: 10.1016/j.jneuroim.2012.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.02.002</ArticleId><ArticleId IdType="pubmed">22370183</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucci S., Consoli F., Valente E.M. Parkinson Disease Genetics: A &#x201c;Continuum&#x201d; from Mendelian to Multifactorial Inheritance. Curr. Mol. Med. 2014;14:1079&#x2013;1088. doi: 10.2174/1566524014666141010155509.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566524014666141010155509</ArticleId><ArticleId IdType="pubmed">25323865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.J. Origins and effects of extracellular alpha-synuclein: Implications in Parkinson&#x2019;s disease. J. Mol. Neurosci. 2008;34:17&#x2013;22. doi: 10.1007/s12031-007-0012-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-007-0012-9</ArticleId><ArticleId IdType="pubmed">18157654</ArticleId></ArticleIdList></Reference><Reference><Citation>Beraud D., Maguire-Zeiss K.A. Misfolded alpha-synuclein and Toll-like receptors: Therapeutic targets for Parkinson&#x2019;s disease. Parkinsonism Relat. Disord. 2012;18(Suppl. 1):S17&#x2013;S20. doi: 10.1016/S1353-8020(11)70008-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(11)70008-6</ArticleId><ArticleId IdType="pmc">PMC3500631</ArticleId><ArticleId IdType="pubmed">22166424</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms A.S., Delic V., Thome A.D., Bryant N., Liu Z., Chandra S., Jurkuvenaite A., West A.B. &#x3b1;-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol. Commun. 2017;5:85. doi: 10.1186/s40478-017-0494-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0494-9</ArticleId><ArticleId IdType="pmc">PMC5698965</ArticleId><ArticleId IdType="pubmed">29162163</ArticleId></ArticleIdList></Reference><Reference><Citation>Codolo G., Plotegher N., Pozzobon T., Brucale M., Tessari I., Bubacco L., de Bernard M. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS ONE. 2013;8:e55375. doi: 10.1371/journal.pone.0055375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055375</ArticleId><ArticleId IdType="pmc">PMC3561263</ArticleId><ArticleId IdType="pubmed">23383169</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Jiang W., Liu L., Wang X., Ding C., Tian Z., Zhou R. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015;160:62&#x2013;73. doi: 10.1016/j.cell.2014.11.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.11.047</ArticleId><ArticleId IdType="pubmed">25594175</ArticleId></ArticleIdList></Reference><Reference><Citation>Junn E., Lee K.W., Jeong B.S., Chan T.W., Im J.Y., Mouradian M.M. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. USA. 2009;106:13052&#x2013;13057. doi: 10.1073/pnas.0906277106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0906277106</ArticleId><ArticleId IdType="pmc">PMC2722353</ArticleId><ArticleId IdType="pubmed">19628698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Lu M., Du R.H., Qiao C., Jiang C.Y., Zhang K.Z., Ding J.H., Hu G. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson&#x2019;s disease. Mol. Neurodegener. 2016;11:28. doi: 10.1186/s13024-016-0094-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0094-3</ArticleId><ArticleId IdType="pmc">PMC4833896</ArticleId><ArticleId IdType="pubmed">27084336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E., Hwang I., Park S., Hong S., Hwang B., Cho Y., Son J., Yu J.W. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26:213&#x2013;228. doi: 10.1038/s41418-018-0124-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0124-5</ArticleId><ArticleId IdType="pmc">PMC6329843</ArticleId><ArticleId IdType="pubmed">29786072</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels M.J.D., Rivers-Auty J., Schilling T., Spencer N.G., Watremez W., Fasolino V., Booth S.J., White C.S., Baldwin A.G., Freeman S., et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer&#x2019;s disease in rodent models. Nat. Commun. 2016;7:12504. doi: 10.1038/ncomms12504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12504</ArticleId><ArticleId IdType="pmc">PMC4987536</ArticleId><ArticleId IdType="pubmed">27509875</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Shao X.Y., Qi G.J., Chen Q., Bu L.L., Chen L.J., Shi J., Ming J., Tian B. Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson&#x2019;s Disease. Mov. Disord. 2016;31:366&#x2013;376. doi: 10.1002/mds.26488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26488</ArticleId><ArticleId IdType="pubmed">26853432</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z., Pan Y.T., Zhang Z.Y., Yang H., Yu S.Y., Zheng Y., Ma J.H., Wang X.M. Systemic activation of NLRP3 inflammasome and plasma &#x3b1;-synuclein levels are correlated with motor severity and progression in Parkinson&#x2019;s disease. J. Neuroinflamm. 2020;17:11. doi: 10.1186/s12974-019-1670-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1670-6</ArticleId><ArticleId IdType="pmc">PMC6950934</ArticleId><ArticleId IdType="pubmed">31915018</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. The Role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med. 2011;11:246&#x2013;254. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D., Baloh R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Investig. 2017;127:3250&#x2013;3258. doi: 10.1172/JCI90607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90607</ArticleId><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F., Molawi K., Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1&#x3b2; accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. USA. 2010;107:13046&#x2013;13050. doi: 10.1073/pnas.1002396107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Debye B., Schm&#xfc;lling L., Zhou L., Rune G., Beyer C., Johann S. Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice. Brain Pathol. 2018;28:14&#x2013;27. doi: 10.1111/bpa.12467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12467</ArticleId><ArticleId IdType="pubmed">27880990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Bell S., Wang J., Wen S., Baloh R.H., Appel S.H. TDP-43 activates microglia through NF-&#x3ba;B and NLRP3 inflammasome. Exp Neurol. 2015;273:24&#x2013;35. doi: 10.1016/j.expneurol.2015.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.019</ArticleId><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S., Heitzer M., Kanagaratnam M., Goswami A., Rizo T., Weis J., Troost D., Beyer C. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63:2260&#x2013;2273. doi: 10.1002/glia.22891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22891</ArticleId><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P., Carlesi C., Giungato P., Puxeddu I., Borroni B., Bossu P., Migliorini P., Siciliano G., Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflamm. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim H., Deltenre P., Martin J.J., Sebire G. In-situ expression of Interleukin-18 and associated mediators in the human brain of sALS patients: Hypothesis for a role for immune-inflammatory mechanisms. Med. Hypotheses. 2016;86:14&#x2013;17. doi: 10.1016/j.mehy.2015.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2015.11.022</ArticleId><ArticleId IdType="pubmed">26804591</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier N.K., Leppla S.H., Moayeri M. The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes. J. Immunol. 2015;194:2776&#x2013;2785. doi: 10.4049/jimmunol.1401611.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1401611</ArticleId><ArticleId IdType="pmc">PMC4355055</ArticleId><ArticleId IdType="pubmed">25681332</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitzer M., Kaiser S., Kanagaratnam M., Zendedel A., Hartmann P., Beyer C., Johann S. Administration of 17beta-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1 (G93A) ALS Mice. Mol. Neurobiol. 2017;54:8429&#x2013;8443. doi: 10.1007/s12035-016-0322-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0322-4</ArticleId><ArticleId IdType="pubmed">27957680</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., van de Veerdonk F.L., van der Meer J.W., Dinarello C.A., Joosten L.A. Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 2015;33:49&#x2013;77. doi: 10.1146/annurev-immunol-032414-112306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032414-112306</ArticleId><ArticleId IdType="pubmed">25493334</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y., Kelley N., He Y. Role of the NLRP3 inflammasome in neurodegenerative diseases and therapeutic implications. Neural Regen Res. 2020;15:1249&#x2013;1250. doi: 10.4103/1673-5374.272576.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.272576</ArticleId><ArticleId IdType="pmc">PMC7047811</ArticleId><ArticleId IdType="pubmed">31960806</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll R.C., Robertson A.A., Chae J.J., Higgins S.C., Mu&#xf1;oz-Planillo R., Inserra M.C., Vetter I., Dungan L.S., Monks B.G., Stutz A., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015;21:248&#x2013;255. doi: 10.1038/nm.3806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3806</ArticleId><ArticleId IdType="pmc">PMC4392179</ArticleId><ArticleId IdType="pubmed">25686105</ArticleId></ArticleIdList></Reference><Reference><Citation>Youm Y.H., Nguyen K.Y., Grant R.W., Goldberg E.L., Bodogai M., Kim D., D&#x2019;Agostino D., Planavsky N., Lupfer C., Kanneganti T.D., et al. The ketone metabolite &#x3b2;-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 2015;21:263&#x2013;269. doi: 10.1038/nm.3804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3804</ArticleId><ArticleId IdType="pmc">PMC4352123</ArticleId><ArticleId IdType="pubmed">25686106</ArticleId></ArticleIdList></Reference><Reference><Citation>Juliana C., Fernandes-Alnemri T., Wu J., Datta P., Solorzano L., Yu J.W., Meng R., Quong A.A., Latz E., Scott C.P., et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem. 2010;285:9792&#x2013;9802. doi: 10.1074/jbc.M109.082305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.082305</ArticleId><ArticleId IdType="pmc">PMC2843228</ArticleId><ArticleId IdType="pubmed">20093358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn H., Kim J., Jeung E.B., Lee G.S. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology. 2014;219:315&#x2013;322. doi: 10.1016/j.imbio.2013.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2013.11.003</ArticleId><ArticleId IdType="pubmed">24380723</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M., Williams K.L., Oliver T., Vandenabeele P., Rajan J.V., Miao E.A., Shinohara M.L. Interferon-&#x3b2; therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci. Signal. 2012;5:ra38. doi: 10.1126/scisignal.2002767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2002767</ArticleId><ArticleId IdType="pmc">PMC3509177</ArticleId><ArticleId IdType="pubmed">22623753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R., Albornoz E.A., Christie D.C., Langley M.R., Kumar V., Mantovani S., Robertson A.A.B., Butler M.S., Rowe D.B., O&#x2019;Neill L.A., et al. Inflammasome inhibition prevents &#x3b1;-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 2018;10:eaah4066. doi: 10.1126/scitranslmed.aah4066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah4066</ArticleId><ArticleId IdType="pmc">PMC6483075</ArticleId><ArticleId IdType="pubmed">30381407</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler B.J., Gelfand B.D., Kim Y., Kerur N., Tarallo V., Hiran Y., Amarnath S., Fowler D.H., Radwan M., Young M.T. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. 2014;346:1000&#x2013;1003. doi: 10.1126/science.1261754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261754</ArticleId><ArticleId IdType="pmc">PMC4274127</ArticleId><ArticleId IdType="pubmed">25414314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>